Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.34 |
| ▸ | GSK3A | P49840 | 10/20 | 0.34 |
| ▸ | AURKA | O14965 | 5/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23524281 | 0.81 | GSK3A (0.43) | GSK3BGSK3AAURKAKDM4ENPC1 | |
| SCHEMBL23524329 | 0.78 | CDK2 (0.41) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL23524173 | 0.77 | CDK2 (0.48) | GSK3BGSK3AAURKA | |
| SCHEMBL30355540 | 0.76 | CDK2 (0.47) | GSK3BGSK3AALDH1A1SMN1; SMN2KDM4C | |
| SCHEMBL23524128 | 0.76 | CDK2 (0.47) | GSK3BGSK3AALDH1A1SMN1; SMN2KDM4C | |
| SCHEMBL30355499 | 0.75 | PARP1 (0.37) | — | |
| SCHEMBL23524050 | 0.75 | PARP1 (0.37) | — | |
| SCHEMBL23523965 | 0.75 | QPCT (0.40) | — | |
| SCHEMBL30355504 | 0.75 | QPCT (0.40) | — | |
| SCHEMBL23523715 | 0.74 | CDK2 (0.49) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | GSK3B 2521/4885GSK3A 2604/4885AURKA 2089/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | GSK3B 2521/4885GSK3A 2604/4885AURKA 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.